Prot # GS-US-342-1139: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Inf

Project: Research project

Project Details

Effective start/end date8/26/148/26/17


  • PRA Health Sciences (GS-US-342-1139)
  • Gilead Sciences, Inc. (GS-US-342-1139)